📰 Mohamed Eid News
Mohamed Eid News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Mohamed Eid. Real-time updates on events, politics, business and more.
April 6, 2024
Results announced from EMPACT-MI phase III trial investigating the effect of Jardiance® on risk of heart failure hospitalization and death in adults following a...
November 17, 2023
Lawyers say French arrest warrant sets ‘historic precedent’ as survivors of chemical massacre long for justice in Syria.
November 5, 2023
Boehringer Ingelheim and Carelon Research have conducted the first large-scale U.S. validation of a new AI-driven tool for chronic kidney disease (CKD) The Klinrisk model predicted disease progression in over 80% of individuals at all stages of the disease, based on data from a diverse population of over 4 million U.S. adults Validated tools to […]
November 4, 2023
/PRNewswire/ -- Boehringer Ingelheim and Carelon Research have conducted a validation study of the Klinrisk model, a machine-learning tool developed to predict...
November 2, 2023
RIDGEFIELD - More than 35 million adults in the U.S. have chronic kidney disease . However, as many as 90% of them are unaware of their condition. This is despite clinical guidelines, which show that...
November 2, 2023
More than 35 million adults in the U.S. have chronic kidney disease (CKD). However, as many as 90% of them are unaware of their condition. This is despite clinical guidelines, which show that using two tests can help detect it. That's why Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced the ...
September 25, 2023
The U.S. Food and Drug Administration (FDA) has approved Jardiance® (empagliflozin) 10 mg tablets to reduce the risk of sustained decline in estimated glomerular filtration rate (eGFR), end-stage kidney disease, cardiovascular death and hospitalization in adults with chronic kidney disease (CKD) at risk of ...
September 22, 2023
Eli Lilly and Company and Boehringer Ingelheim announced the FDA approval of empagliflozin (Jardiance) for chronic kidney disease management on September 22, 2023.
September 22, 2023
This approval marks the fourth endorsement by the FDA for empagliflozin, all of which have been linked to the EMPOWER program.
September 22, 2023
The approval comes weeks after the Biden administration announced Jardiance was among the first 10 prescription drugs selected for Medicare price negotiations under the Inflation Reduction Act.